Ismail Ismailoglu, PhD
Ismail Ismailoglu, PhD, is a Manager at CBPartners, working across a variety of practices to address a range of commercial business issues.
Tumor-Agnostic Therapies: The Complex Path to Commercial Viability
24 March 2020
Genome Editing: An Introduction
4 March 2020
American Society for Hematology (ASH) 2019 Annual Meeting: Our Recommended CAR T Cell Therapy Innovation Talks
22 November 2019
Do Cutting-Edge One-Time Treatments Need Equally Innovative Outcomes or Annuity Based Payment Models?
17 August 2018
CAR-T Combos: Potentially the Next Big Thing in Solid Tumors, Yet Pricing ‘Sticker Shock’ is not the Only Hurdle to be Overcome
5 March 2018
Does the Fate of MS Pricing Lie in the Hands of Politicians or Manufacturers?
17 September 2017
Strategic Patient Advocacy vs. Evidence Package: The “Rare” Challenge for Orphan Drug Manufacturers
28 February 2017